ketamine / Generic mfg. - LARVOL DELTA

Early outcomes with a standardized admission order set for sickle cell crisis: A real-world single-institution retrospective review (ASH 2025) - "The order set was created through a collaborative effort by hematologists at our institution and included medications like a reminder to reorder home hydroxyurea if appropriate, daily folic acid tablets, adjunct pain medications and options for opioid pain regimens, options for hypotonic and regular intravenous (IV) fluids to order on admission, labs on admission, daily labs some of which were pre-selected, quick access to order bowel regimens, deep vein thrombosis (DVT) prophylaxis and incentive spirometry...Mean length of hospital stay was 7 days (range 1 - 25 days), 4% of patients required ICU level of care (vs 3.8% in the pre-intervention study, p=0.96) and 3 other patients required ICU monitoring for ketamine infusion per institute policy... Our single institute study demonstrates improvement in sickle cell crisis quality of care measures especially with higher admission order metrics such as DVT prophylaxis, bowel regimen, IV fluids and usage of PCA for adequate..."

Real-world • Real-world evidence • Retrospective data • Review • Cardiovascular • Genetic Disorders • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Sickle Cell Disease • Thrombosis

Healthcare utilization in patients with sickle cell disease on buprenorphine for chronic pain (ASH 2025) - "The studywas performed at the University of Chicago Medical Center and included patients aged 18 years andolder with a confirmed diagnosis of SCD (HbSS, HbSC, or HbSbeta0).Patients with acute-on-chronic pain were offered BUP if they were admitted for at least 7 days on IVopioids and unable to wean despite offering Ketamine or Lidocaine, or if they had at least 2 admissions inthe last 30 days. Patients on chronic opioid therapy with methadone or a prior diagnosis of opioid usedisorder were excluded from the study...Concurrent opioidutilization was assessed through prescription records, documenting daily morphine milligram equivalents(MME) for breakthrough opioid therapy.Primary outcomes included admission (Adm) rates and average length of stay (LOS) per admission,captured from inpatient encounter records...Otherfactors, such as access to outpatient care, psychosocial support, or disease-modifying therapies likehydroxyurea, may also have influenced outcomes.This study..."

Clinical • HEOR • Genetic Disorders • Hematological Disorders • Pain • Sickle Cell Disease • Substance Abuse

The Effect of Exposure to Music on Spatial Learning and Memory in Rats. (PubMed, Noro Psikiyatr Ars) - "For the remaining two groups, one was injected with ketamine and the other was injected with MK-801. The effect of music on NMDARs may be at levels that do not change PPI values. Considering that parameters like the duration and intensity of music may cause stress, repeating the experiment with different conditions may provide new clues."

Journal • Preclinical

Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. (clinicaltrials.gov) - P2/3 | N=30 | Not yet recruiting | Sponsor: The Ketamine Research Foundation

New P2/3 trial • Musculoskeletal Pain • Pain

Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy. (PubMed, Aust N Z J Psychiatry) - "In this article, we consider ketamine's psychiatric use through the lens of medical ethics, structured around the principles of autonomy, beneficence, non-maleficence and justice. We argue that while ketamine should be embraced as a legitimate psychiatric therapy, its application must be grounded in rigorous ethical practice, supported by regulation and research, and shielded from both undue dismissal and premature over-promotion."

Journal • CNS Disorders • Depression • Mental Retardation • Psychiatry

Ketamine's uncertain efficacy and pregabalin's heart failure risk: lessons for safer pain care in older adults. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Pain

Ketamine enantiomers and the gut microbiota: mechanisms, clinical implications, and future directions. (PubMed, Mol Biol Rep) - No abstract available

Journal • Review • CNS Disorders • Depression • Psychiatry

Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation. (PubMed, Mol Neurobiol) - "In vivo, CBD alleviated SCZ-like symptoms in a ketamine-induced animal model, reducing anxiety in the open field (p < 0.01) and elevated plus maze tests (p < 0.01), improving spatial memory in the Y-maze (p < 0.01) and social behavior (p < 0.0001) after 5 consecutive days of treatment. Critically, we validated CBD's central anti-inflammatory effects by demonstrating reduced pro-inflammatory cytokine levels in both plasma and brain tissues (p < 0.05). Further correlation analysis established a direct link between brain cytokine suppression and behavioral improvements, integrating in vitro findings from BV2 microglial cells with in vivo neuroinflammatory and behavioral outcomes.These findings suggest the potential therapeutic benefits of CBD for SCZ, though further research, particularly clinical trials, is required to validate its efficacy and establish it as a novel therapeutic strategy."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia • IL1B • IL6 • TNFA

The nitric oxide synthase inhibitor 7-nitroindazole attenuates social withdrawal and memory impairments induced by Blockade of the NMDA receptor in the rat. (PubMed, Psychopharmacology (Berl)) - "The present results indicate that 7-NI is sensitive to glutamate blockade since it decreased behavioural impairments resembling the negative symptoms and cognitive deficits of schizophrenia. Moreover, these findings corroborate the potential of 7-NI as an adjunctive molecule for the medication of schizophrenia."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia • NOS1

Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults. (PubMed, N Engl J Med) - P4 | "Among critically ill adults undergoing tracheal intubation, the use of ketamine to induce anesthesia did not result in a significantly lower incidence of in-hospital death by day 28 than etomidate. (Funded by the Patient-Centered Outcomes Research Institute and others; RSI ClinicalTrials.gov number, NCT05277896.)."

Intubation • Journal • Anesthesia • Cardiovascular • Critical care

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries (clinicaltrials.gov) - P4 | N=67 | Completed | Sponsor: Northwestern University | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Obstetrics • Pain • Postpartum Depression • Psychiatry

Perioperative Multimodal General Anesthesia Focusing on Specific Central Nervous System Targets Does Not Reduce Postoperative Interleukin-6 and Neurofilament Light Levels in Patients Undergoing Cardiac Surgeries: A Randomized Controlled Trial. (PubMed, J Cardiothorac Vasc Anesth) - "MMGA did not reduce postoperative IL-6 or NFL levels, nor did it improve neurocognitive outcomes, compared with standard of care. The higher burst suppression in the MMGA group underscores the need for structured EEG education among cardiac anesthesiologists. Future studies should explore other EEG metrics and multimodal strategies for perioperative brain protection."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Cognitive Disorders • Pain • IL6 • NEFL

It's Not Just the Ketamine: Perioperative Care and Postoperative Delirium. (PubMed, Anesthesiology) - No abstract available

Journal • CNS Disorders

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine. (PubMed, Ther Adv Psychopharmacol) - "Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional treatments...Modern methods for predicting treatment response will allow clinicians to personalise psychedelic interventions to the individual, capitalising on quantitative evidence to provide precision medical care. This review serves to identify limitations of the current treatment paradigm for PTSD, highlight how emerging psychedelic interventions may offer a solution to these considerations and explore the promise of precision medicine approaches for the future of PTSD treatment."

Journal • Review • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

KET-PD: Ketamine for the Treatment of Depression in Parkinson's Disease (clinicaltrials.gov) - P2 | N=51 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

ACT_for Alcohol Use Disorder and Depression (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Not yet recruiting ➔ Recruiting | N=20 ➔ 30 | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: Nov 2025 ➔ Aug 2026

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial. (PubMed, NPJ Digit Med) - "In a Phase II ketamine trial for treatment-resistant depression (n = 63), NetraAI analyzed psychiatric scale data (175/patient) and MRI-derived features (185/patient)...These findings demonstrate that an explainable dynamical AI approach can leverage small but rich datasets to uncover hidden clinically meaningful subgroups. NetraAI's precision enrichment strategy has the potential to improve trial success rates and enable personalized medicine by prospectively identifying patients most likely to benefit from a given therapy in oncology, psychiatry, neurodegeneration, and for other disorders."

Journal • P2 data • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry

SEDCOG: Effects of Different Sedation Techniques on Early Cognitive Recovery After Ambulatory Gynecologic Surgery (clinicaltrials.gov) - P=N/A | N=120 | Completed | Sponsor: Sait Fatih Öner

New trial • Anesthesia • Gynecology

Nektar: Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Dr. med. Marcus Herdener | Not yet recruiting ➔ Recruiting

Enrollment open • Addiction (Opioid and Alcohol)

Stability of emergency medications during extreme cold: a controlled environmental study. (PubMed, Scand J Trauma Resusc Emerg Med) - "Emergency medications can remain chemically stable under extreme cold conditions when stored in sealed, insulated packaging. While our study simulated prehospital conditions without direct environmental exposure, these findings support the feasibility of extended storage and transport of emergency medications in challenging field settings. Further research should assess the impact of direct environmental exposure and evaluate additional stability parameters to optimize storage protocols in real-world scenarios."

Journal

Integrated metabolomics and gut microbiota analysis to explore the potential mechanism of levo-tetrahydropalmatine against ketamine addiction. (PubMed, Front Pharmacol) - "Moreover, Spearman's correlation analysis showed that discriminative metabolites were closely correlated with special bacteria. The findings demonstrated that l-THP might serve as a promising intervention strategy for KET addiction by regulating serum and urine metabolism and gut microbiota."

Journal • CNS Disorders • Metabolic Disorders • Psychiatry • Substance Abuse

Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review. (PubMed, J Psychopharmacol) - "There are indications that es/ketamine pharmacotherapy may reduce pathological anxiety, although relapse may follow its termination. More studies are needed to confirm these preliminary findings."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry

TREASURE: InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (clinicaltrials.gov) - P3 | N=31 | Not yet recruiting | Sponsor: Sunnybrook Health Sciences Centre | Trial completion date: Nov 2026 ➔ Dec 2027 | Initiation date: Mar 2025 ➔ Jan 2026 | Trial primary completion date: Nov 2026 ➔ Dec 2027

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Novel and emerging anesthetic drugs for the treatments of major depression: a comprehensive review of efficacy, mechanism, and outlook. (PubMed, Front Psychiatry) - "Clinical and preclinical studies increasingly support the antidepressant potential of several anesthetic agents, including ketamine, propofol, nitrous oxide (N2O), sevoflurane, and isoflurane. This review summarizes recent advances in both experimental and clinical research on the antidepressant effects of anesthetics, highlighting their underlying molecular and neural mechanisms, therapeutic potential, and current limitations. By integrating mechanistic insights with translational evidence, this article provides new perspectives and serves as a reference for future research aimed at developing safe and effective anesthetic-based therapies for treatment-resistant depression."

Journal • Review • Anesthesia • CNS Disorders • Depression • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry

Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients (clinicaltrials.gov) - P4 | N=90 | Recruiting | Sponsor: Texas Tech University Health Sciences Center | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Depression • Orthopedics • Pain • Post-traumatic Stress Disorder • Psychiatry